Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 21 of 21 publications.

Vass C, Pinto CA, Myers K, Imai K, Bussberg C, Bhattacharya R, Calhoun SR, Poulos C. Oncologists' and urologists' preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment. Future Oncol. 2025 Mar;21(7):833-42. doi: 10.1080/14796694.2025.2464485

Calhoun SR, Vass C, Myers K, Imai K, Bussberg C, Bhattacharya R, Pinto CA, Poulos C. Patient preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment. Future Oncol. 2025 Mar;21(7):843-51. doi: 10.1080/14796694.2025.2463276

Ailawadhi S, Inocencio TJ, Mansfield C, Chintakayala P, Bussberg C, Chi L, Harnett J, Kroog GS, Rodriguez-Lorenc K, Ma Q. Patient preferences for triple-class–exposed relapsed or refractory multiple myeloma treatment: a discrete-choice study. Future Oncol. 2025 Mar;21(7):853-65. doi: 10.1080/14796694.2025.2461430

Passamonti F, Korgaonkar S, Parikh RC, Chevli M, Yucel A, Rombi J, Jones S, Zissler D, Davis KL, Slaff S. Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib. Future Oncol. 2025 Feb;21(5):579-91. doi: 10.1080/14796694.2025.2454895

Ravelo A, Myers K, Brumble R, Bussberg C, Koffman B, Manzoor BS, Biondo JML, Mansfield C. Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment. Future Oncol. 2024;20(28):2059-70. doi: 10.1080/14796694.2024.2348440

Diez-Campelo M, Yucel A, Goyal RK, Parikh RC, Esterberg E, Jimenez M, Sluga-O'Callaghan M, Miteva D, Xiao H, Germing U. Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe. Future Oncol. 2024;20(27):1993-2004. doi: 10.1080/14796694.2024.2379228

Furqan M, Karanth S, Goyal RK, Cai B, Rombi J, Davis KL, Caro N, Saliba T. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study. Future Oncol. 2024;20(22):1553-63. doi: 10.2217/fon-2023-1064

Paik PK, Goyal RK, Cai B, Price MA, Davis KL, Derrien Ansquer V, Caro N, Saliba TR. Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib. Future Oncol. 2023 Jan;19(3):217-28. doi: 10.2217/fon-2022-1133

DeBusk K, Abeysinghe S, Vickers A, Nangia A, Bell J, Ike C, Forero-Torres A, Blahna MT. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. Future Oncol. 2021 Nov;17(33):4635-47. doi: 10.2217/fon-2021-0742

Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA. Future Oncol. 2021 Jul;17(21):2759-68.

Mansfield C, Myers K, Klein K, Patel J, Nakasato A, Ling YL, Tarhini AA. Risk tolerance in adjuvant and metastatic melanoma settings: a patient perspective study using the threshold technique. Future Oncol. 2021 Jun;17(17):2151-67. doi: 10.2217/fon-2020-1193

Tripathy D, Blum JL, Rocque GB, Bardia A, Karuturi MS, Cappelleri JC, Liu Y, Zhang Z, Davis KL, Wang Y. POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer. Future Oncol. 2020 Nov;16(31):2475-85. doi: 10.2217/fon-2020-0573

Vassilev ZP, Soriano Gabarro M, Kaye JA, Saltus CW, Riedel O, Scholle O, Mehtala J, Korhonen P, Garbe E, Zong J. Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: results from observational studies in three countries. Future Oncol. 2020 Sep;16(25):1889-901. doi: 10.2217/fon-2020-0315

Hoffman V, Xue F, Ezzy SM, Yusuf A, Green E, Eisele O, Kurth T, Seeger JD. Risk of cardiovascular and cerebrovascular events and mortality in patients with migraine receiving prophylactic treatments: an observational cohort study. Cephalalgia. 2019 Oct;39(12):1544-59. doi: 10.1177/0333102419856630

Hoffman V, Xue F, Ezzy SM, Yusuf A, Green E, Eisele O, Kurth T, Seeger JD. Risk of cardiovascular and cerebrovascular events and mortality in patients with migraine treated with prophylactic medications: an observational cohort study. Cephalalgia. 2019 Oct;39(12):1544-59. doi: 10.1177/0333102419856630

Meyers JL, Davis KL, Lenz RA, Sakai F, Xue F. Treatment patterns and characteristics of patients with migraine in Japan: a retrospective analysis of health insurance claims data. Cephalalgia. 2019 Oct;39(12):1518-34. doi: 10.1177/0333102419851855

Darden C, Mitra D, McSorley D, Davis K, Band J, Iyer S. Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer. Future Oncol. 2019 Jan;15(2):141-50. doi: 10.2217/fon-2018-0531

Matharu M, Pascual J, Nisson Remahl I, Straube A, Lum A, Davar G, Odom D, Bennett L, Proctor C, Gutierrez L, Andrews E, Johannes C. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia. 2017 Dec;37(14):1384-97. doi: 10.1177/0333102417724150

Matharu M, Pascual J, Nilsson Remahl L, Straube A, Johannes C, Odom D, Gutierrez L, Andrews E, Lum A. Interim analysis of the real-world utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in an observational study in the European Union. Poster presented at the International Headache Conference; May 14, 2015. Valencia, Spain. [abstract] Cephalalgia. 2015; 35(6S):39.

Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.

Burch SP, Davis KH, Fehnel SE, Nelsen AC, Hill CD, Shashidhar KH. Outcomes, impact and behavior associated with acute treatment of migraine. Poster presented at the 16th Migraine Trust International Symposium; November 2006. [abstract] Cephalalgia. 2006 Nov; 26(11):1358-403.